RxDoctor Payments Data

Jose Vallejos, MD

Internal Medicine · Dallas, TXNPI 1427239409

Payments from drug & device makers

$1,485in general payments, 2019–2025

Across 90 payments — averaging $16.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$231
  • GSK$221
  • Amgen$126
  • Pfizer$122
  • Novartis$94
  • Lilly USA, LLC$94
  • plus $598 from 15 others

What the payments were for

  • Food & beverage$1,47499%
  • Education$111%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,485 in reported general payments places this provider in the 70th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$93,413
Medicare patients
233
Services billed
3,161

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide123$192,694
JanuviaSitagliptin Phosphate105$137,535
TrulicityDulaglutide66$135,417
EliquisApixaban119$131,406
Trelegy ElliptaFluticasone/Umeclidin/Vilanter69$71,309
TriumeqAbacavir/Dolutegravir/Lamivudi12$44,071
MounjaroTirzepatide15$39,869
DescovyEmtricitabine/Tenofov Alafenam13$33,262
JardianceEmpagliflozin13$19,903
XareltoRivaroxaban19$18,203
SymbicortBudesonide/Formoterol Fumarate38$15,950
EntrestoSacubitril/Valsartan14$15,243
CreonLipase/Protease/Amylase13$14,946
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$14,006
MyrbetriqMirabegron11$13,658

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$231$192,694123 claims
Lilly USA, LLCTrulicity, Mounjaro$94$175,28681 claims
MerckJanuvia$18$137,535105 claims
PfizerEliquis$122$131,406119 claims
GSKTrelegy Ellipta$221$71,30969 claims
AstraZenecaSymbicort, Breztri Aerosphere$79$29,95652 claims
NovartisEntresto$94$15,24314 claims
AbbVieCreon$62$14,94613 claims
Astellas Pharma US IncMyrbetriq$46$13,65811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →